0001493152-24-000035.txt : 20240102 0001493152-24-000035.hdr.sgml : 20240102 20240102085242 ACCESSION NUMBER: 0001493152-24-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240102 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240102 DATE AS OF CHANGE: 20240102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAXOR CORP CENTRAL INDEX KEY: 0000027367 ORGANIZATION NAME: IRS NUMBER: 132682108 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 811-22684 FILM NUMBER: 24500452 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 4740 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 212-330-8500 MAIL ADDRESS: STREET 1: 350 5TH AVENUE STREET 2: SUITE 4740 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: IDANT CORP DATE OF NAME CHANGE: 19730823 8-K 1 form8-k.htm
false 0000027367 0000027367 2024-01-02 2024-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 2, 2024

 

Daxor Corporation

(Exact name of registrant as specified in its charter)

 

New York   811-22684   13-2682108
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

109 Meco Lane, Oak Ridge, TN   37830
(Address of principal executive offices)   (Zip Code)

 

212-330-8500

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock $0.01 par value   DXR   Nasdaq

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

 

 
 

 

Item 8.01 – Other Events

 

On January 2, 2024 Daxor Corporation announced it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company’s mission is to advance healthcare by enabling optimal fluid management. The press release issued is attached to this filing as Exhibit 99.1

 

Item 9.01 Exhibits

 

(d) Exhibits. The following exhibit is filed with this Current Report on Form 8-K:

 

No.   Description
     
99.1   Press release dated January 2, 2024 – Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  DAXOR CORPORATION
  (Registrant)
     
Date: January 2, 2024 By: /s/ Robert J. Michel
  Name: Robert J. Michel
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

 

The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside

 

Oak Ridge, TN – January 2, 2024 -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The Company’s mission is to advance healthcare by enabling optimal fluid management.

 

The new Daxor BVA device directly quantifies the intravascular blood, red blood cell and plasma volume, providing clinicians with actionable information to achieve optimal fluid management for their patients. Compared to the current Daxor BVA-100 system, the new Daxor BVA is designed to be three times faster, simpler to operate, completely portable, and capable of performing bedside analysis, making it easier for healthcare providers to integrate this innovative diagnostic into their clinical workflow.

 

“Today marks a long-anticipated and momentous milestone in our continued commitment to our customers, patients, and to achieving our vision of optimal blood volume for all,” said Michael Feldschuh, Daxor’s CEO and President. “Funded under contract by the U.S. Department of Defense, our next-generation analyzer will deliver a level of speed, access, and accuracy to blood volume management that can significantly improve care and outcomes in medicine.”

 

About Daxor Corporation

 

Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.

 

Forward-Looking Statements

 

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Contact:

 

Bret Shapiro

Sr. Managing Partner, CORE IR

1-516-222-2560

brets@coreir.com

 

   

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 dxr-20240102.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 dxr-20240102_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 dxr-20240102_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 02, 2024
Entity File Number 811-22684
Entity Registrant Name Daxor Corporation
Entity Central Index Key 0000027367
Entity Tax Identification Number 13-2682108
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 109 Meco Lane
Entity Address, City or Town Oak Ridge
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37830
City Area Code 212
Local Phone Number 330-8500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock $0.01 par value
Trading Symbol DXR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000027367 2024-01-02 2024-01-02 iso4217:USD shares iso4217:USD shares false 0000027367 8-K 2024-01-02 Daxor Corporation NY 811-22684 13-2682108 109 Meco Lane Oak Ridge TN 37830 212 330-8500 false false false false Common Stock $0.01 par value DXR NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://daxor.com/role/Cover Cover Cover 1 false false All Reports Book All Reports dxr-20240102.xsd dxr-20240102_lab.xml dxr-20240102_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "DXR", "nsuri": "http://daxor.com/20240102", "dts": { "schema": { "local": [ "dxr-20240102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "dxr-20240102_lab.xml" ] }, "presentationLink": { "local": [ "dxr-20240102_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://daxor.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://daxor.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-000035-xbrl.zip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